Skip to content

Inflammation Indicators in Saliva from children and adolescents with Spastic Cerebral Palsy

Salivary Biomarkers associated with Gingivitis in children and adolescents with Spastic Cerebral Palsy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-2yfbnp
Enrollment
Unknown
Registered
2017-10-25
Start date
2017-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy

Interventions

Group with moderate gingivitis: 30 children or adolescents with cerebral palsy, and more than 20% bleeding during evaluation of the gingiva. Saliva will be collected to assess the amount of inflammati
Procedure/surgery
Other

Sponsors

Universidade Cruzeiro do Sul
Lead Sponsor
Associação de Assistência à Criança Deficiente
Collaborator

Eligibility

Age
No minimum to 14 Years

Inclusion criteria

Inclusion criteria: Will be included in this study individuals with a medical diagnosis of spastic type CP.

Exclusion criteria

Exclusion criteria: Will be excluded individuals with progressive or neurodegenerative lesions will be excluded; Individuals with CP who are taking any drug that interferes with salivary secretion such as anticholinergics, neuroleptics or benzodiazepines for at least 72 hours prior to salivary collection; Or have undergone surgical procedures to control the external flow of saliva. Still, individuals who do not collaborate with the salivary collection have used antibiotics in the last month, present symptoms of fever, flu, body aches or diarrhea, or even an inflammatory condition on the oral mucosa as a cold sore.

Design outcomes

Primary

MeasureTime frame
The expected outcome is the reduction in the level of inflammatory markers in saliva. The method used to verify the expected outcome will be the evaluation of the level of Interleukin 1beta, Interleukin 6, Interleukin 8, Interleukin 10, Tumor Necrosis Factor and Interleukin 12p70 in saliva. The parameter to be used to evaluate the occurrence of the outcome will be a reduction of at least 50% in the level of the inflammatory cytokines. Clinical evaluations and saliva collection will be performed before and after treatment for gingivitis.

Secondary

MeasureTime frame
The expected outcome is the reduction of the degree of gingivitis. The method used to verify the expected secondary outcome will be the evaluation of the Gingival Index. The parameter to be used to evaluate the occurrence of the outcome will be the verification of a reduction of 50% in the measurements before and after periodontal treatment.

Countries

Brazil

Contacts

Public ContactMaria Teresa Santos

Universidade Cruzeiro do Sul

maria.botti@cruzeirodosul.edu.br+5511999722301

Outcome results

None listed

Source: REBEC (via WHO ICTRP)